Mutual of America Capital Management LLC purchased a new stake in BioLife Solutions, Inc. (NASDAQ:BLFS – Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 400,916 shares of the medical equipment provider’s stock, valued at approximately $8,592,000. Mutual of America Capital Management LLC owned about 0.87% of BioLife Solutions at the end of the most recent quarter.
Other institutional investors and hedge funds also recently bought and sold shares of the company. 1620 Investment Advisors Inc. acquired a new stake in BioLife Solutions in the 2nd quarter valued at about $35,000. Register Financial Advisors LLC purchased a new stake in BioLife Solutions during the first quarter valued at about $96,000. Arizona State Retirement System purchased a new stake in BioLife Solutions during the second quarter valued at about $217,000. Legato Capital Management LLC purchased a new stake in BioLife Solutions during the second quarter valued at about $233,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in BioLife Solutions during the first quarter valued at about $229,000. 93.24% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, insider Sarah Aebersold sold 3,000 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $21.03, for a total value of $63,090.00. Following the transaction, the insider now owns 61,683 shares in the company, valued at $1,297,193.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other BioLife Solutions news, CRO Garrie Richardson sold 3,070 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $25.12, for a total transaction of $77,118.40. Following the transaction, the executive now owns 114,773 shares in the company, valued at $2,883,097.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Sarah Aebersold sold 3,000 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $21.03, for a total value of $63,090.00. Following the transaction, the insider now owns 61,683 shares in the company, valued at approximately $1,297,193.49. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 9,944 shares of company stock worth $229,709. Insiders own 2.20% of the company’s stock.
BioLife Solutions Price Performance
BioLife Solutions (NASDAQ:BLFS – Get Free Report) last issued its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.08. The company had revenue of $28.33 million for the quarter, compared to the consensus estimate of $23.80 million. BioLife Solutions had a negative return on equity of 10.75% and a negative net margin of 59.88%. Equities research analysts expect that BioLife Solutions, Inc. will post -0.36 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of analysts have commented on BLFS shares. TD Cowen upped their price objective on shares of BioLife Solutions from $20.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, July 17th. Northland Securities upped their price objective on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Finally, Craig Hallum upped their price objective on shares of BioLife Solutions from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, August 12th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $26.20.
Check Out Our Latest Analysis on BLFS
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
See Also
- Five stocks we like better than BioLife Solutions
- How to Calculate Stock Profit
- How Much Can You Make in Stocks in One Month?
- How to Use Stock Screeners to Find Stocks
- This Is the Top Large-Cap Stock Insiders Are Buying
- The Basics of Support and Resistance
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.